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Abstract
Introduction: Lead (Pb) is known to affect bone, and recent evidence suggests that it has effects on cartilage as
well. As osteoarthritis (OA) is a highly prevalent disease affecting bone and cartilage, we undertook the present
analysis to determine whether whole blood Pb levels are associated with radiographic and symptomatic OA (rOA
and sxOA, respectively) of the knee.
Methods: The analysis was conducted using cross-sectional data from the Johnston County Osteoarthritis Project,
a rural, population-based study, including whole blood Pb levels, bilateral posteroanterior weight-bearing knee
radiography and knee symptom data. rOA assessment included joint-based presence (Kellgren-Lawrence (K-L)
grade 2 or higher) and severity (none, K-L grade 0 or 1; mild, K-L grade 2; moderate or severe, K-L grade 3 or 4), as
well as person-based laterality (unilateral or bilateral). SxOA was deemed present (joint-based) in a knee on the
basis of K-L grade 2 or higher with symptoms, with symptoms rated based on severity (0, rOA without symptoms;
1, rOA with mild symptoms; 2, rOA with moderate or severe symptoms) and in person-based analyses was either
unilateral or bilateral. Generalized logit or proportional odds regression models were used to examine associations
between the knee OA status variables and natural log-transformed blood Pb (ln Pb), continuously and in quartiles,
controlling for age, race, sex, body mass index (BMI), smoking and alcohol drinking.
Results: Those individuals with whole blood Pb data (N = 1,669) had a mean (±SD) age of 65.4 (±11.0) years and a
mean BMI of 31.2 (±7.1) kg/m2, including 66.6% women and 35.4% African-Americans, with a median blood Pb
level of 1.8 μg/dl (range, 0.3 to 42.0 μg/dl). In joint-based analyses, for every 1-U increase in ln Pb, the odds of
prevalent knee rOA were 20% higher (aOR, 1.20; 95% CI, 1.01 to 1.44), while the odds of more severe rOA were
26% higher (aOR, 1.26; 95% CI, 1.05 to 1.50, under proportional odds). In person-based analyses, the odds of
bilateral rOA were 32% higher for each 1-U increase in ln Pb (aOR, 1.32; 95% CI, 1.03 to 1.70). Similarly for knee
sxOA, for each 1-U increase in ln Pb, the odds of having sxOA were 16% higher, the odds of having more severe
symptoms were 17% higher and the odds of having bilateral knee symptoms were 25% higher. Similar findings
were obtained with regard to ln Pb in quartiles.
Conclusions: Increases in the prevalence and severity measures for both radiographically and symptomatically
confirmed knee OA (although statistically significant only for rOA) were observed with increasing levels of blood
Pb, suggesting that Pb may be a potentially modifiable environmental risk factor for OA.
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Introduction
Osteoarthritis (OA) is the most common form of arthri-
tis, affecting approximately 27 million U.S. adults [1].
While some risk factors for OA of the knee are known,
such as older age and obesity [2], the disease process
remains poorly understood and no effective disease-
modifying treatments are currently available. Regional
differences in arthritis prevalence [3] are suggestive of a
possible contribution of environmental factors. There is
a precedent for environmental factors to cause arthritis,
as in Kashin-Beck disease, an endemic arthropathy lar-
gely confined to areas of China and Tibet, which is
thought to be at least in part related to selenium defi-
ciency [4]. Mseleni joint disease in Africa and Handi-
godu disease in India are other arthropathies thought to
have an environmental contribution [5,6]. Hereditary
hemochromatosis, a genetic disorder of metabolism of
iron and other heavy metals [7], is frequently associated
with an arthropathy with features similar to those of
OA [8,9]. Given these observations, we considered the
possibility of environmental metal exposure as a novel
risk factor for OA.
Lead (Pb) is ubiquitous in the environment, and
although overall exposure in the United States has been
on the decline [10,11], regional differences remain [12].
Approximately 95% of the total body Pb burden in
adults is stored in bone and has a half-life of decades
[13], which contributes as much as 65% to measured
whole blood Pb levels [14]. Pb deposition has been
observed in cartilage and bone in human OA [15,16]
and is measurable in the synovial fluid of individuals
with knee OA without a history of excessive metals
exposure [17]. Pb stored in bone is released chronically
into the blood pool, especially during times of increased
bone turnover, such as menopause [18,19], and poten-
tially during bone remodeling as seen in OA. This
makes bone both a target tissue for Pb toxicity and a
persistent endogenous source of Pb [20-24]. Even mild
elevations in blood Pb levels may have health conse-
quences, including increased mortality, as shown by
recent studies based on data from the Third National
Health and Nutrition Examination Survey [25] and the
Study of Osteoporotic Fractures [26].
Long-term exposure to Pb may affect bone and other
joint structures in humans. Pb interferes with regulatory
aspects of bone cellular function and matrix synthesis,
with effects on dietary calcium uptake and metabolism
and conversion of vitamin D to 1,25-OH vitamin D
[23,27,28]. Pb exposure affects the function of bone
remodeling cells, causing impaired collagen synthesis by
osteoblasts and impaired resorptive capacity of osteo-
clasts [28]. In a study of bone samples from individuals
without known bone disease or Pb exposure, researchers
identified marked accumulation of Pb specifically at the
cartilage tidemark, which is the transition point between
the calcified and noncalcified cartilaginous matrix [29],
where clefts occur as OA develops. Zuscik and collea-
gues [30] reported reversion of articular chondrocytes to
a more primitive phenotype upon Pb exposure, with
matrix degradation and mineralization as well as chon-
drocyte hypertrophy. A related study revealed impaired
fracture healing in Pb-exposed mice, with associated
delays in endochondral maturation [31]. The affinity of
Pb for joint tissues, as well as the apparent role of Pb in
cartilage and bone maturation and repair, suggests a
potential role for Pb in the OA disease process, in
which there is an imbalance of bone and cartilage remo-
deling with prominent involvement of the tidemark area
of the cartilaginous matrix.
The current analysis uses data from the Johnston
County Osteoarthritis Project, a population-based longi-
tudinal cohort of individuals with or without OA in
rural North Carolina. Residential sources of Pb contami-
nation remain a problem in North Carolina, and rural
areas have a higher percentage of older, pre-1950 hous-
ing than urban areas [32]. In addition, pesticides con-
taining Pb and arsenic were in widespread use in North
Carolina well into the latter half of the 20th century
before they were banned and before occupational pro-
tective regulations became routine. Almost 20% of our
study participants have farmed for at least 1 year of
their lives. These potential exposures suggest that this
population may have a wider range of Pb values than
other populations and therefore may be useful in explor-
ing potential effects of Pb on OA. Using data from this
well-defined cohort, we performed a cross-sectional ana-
lysis to determine whether there were associations
between whole blood Pb levels and either radiographi-
cally determined OA (rOA) or symptomatically deter-
mined OA (sxOA) at the knee.
Materials and methods
This was a cross-sectional study using data from the
Johnston County Osteoarthritis Project, a population-
based study of OA in rural Johnston County, NC, USA.
Details of this study have been reported previously [33].
Briefly, the study participants were civilian, noninstitu-
tionalized, African-American or Caucasian adults ages
45 years and older recruited by probability sampling in
six townships beginning in 1991. The Metals Exposure
Sub-Study, including whole blood Pb assessment, was
designed to consist of 1,700 consecutive individuals
either newly enrolled during cohort enrichment in 2003
and 2004 or returning for a second follow-up visit
between 2006 and 2008. The cohort enrichment sample
was enriched for younger individuals, men and African
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American individuals, who were lost in a higher propor-
tion than other participants over the follow-up period
from study initiation [34]. Whole blood Pb levels were
obtained for a total of 1,669 individuals at the same
clinic visit at which radiography was performed. This
study has been approved by the institutional review
boards of the Centers for Disease Control and Preven-
tion and the University of North Carolina, and all parti-
cipants provided informed consent prior to participation
in the study.
Radiographically confirmed knee OA
Participants underwent bilateral posteroanterior fixed-
flexion radiography of the knees in weight-bearing as
previously described [33]. All films were read by a single
musculoskeletal radiologist (JBR) previously shown to
have high inter- and intrarater reliability ( = 0.86 and
 = 0.89, respectively) [35]. Knee radiographs were
graded according to the Kellgren-Lawrence (K-L) classi-
fication scheme (from 0 to 4). Knee rOA (joint-based)
was diagnosed if a knee had a K-L grade ≥2. The sever-
ity of rOA was considered at three levels: none (K-L
grade 0 or 1), mild (K-L grade 2) or moderate or severe
(K-L grade 3 or 4) for each knee. Bilateral rOA was
defined as a K-L grade ≥2 in both knees, and unilateral
rOA was defined as a K-L grade ≥2 in only one knee
(person-based).
Symptomatically confirmed knee OA
All participants completed symptom questionnaires. A
sxOA diagnosis (joint-based) was made on the basis of
the presence of rOA (K-L grade ≥2) and an affirmative
answer to the question, “On MOST days do you have
pain, aching or stiffness in your knees?” which was
asked separately with regard to each knee. The severity
of sxOA was based on the question, “Is the pain, aching
or stiffness in your knees mild, moderate, or severe?”
which was also asked with regard to each knee, coded
according to three categories (0, rOA without symp-
toms, 1, rOA with mild symptoms; and 2, rOA with
moderate or severe symptoms). Bilateral sxOA was
defined as the conjoint occurrence of at least mild
symptoms in the presence of rOA in each knee (person-
based). Unilateral sxOA required at least mild symptoms
in one knee with rOA and no symptoms in the other
knee (regardless of rOA status).
Blood Pb level
Whole blood was collected utilizing certified metal-free
blood drawing equipment and vials and was stored at
approximately 4°C [36,37] until shipment in batches of
50 to 100 to the Division of Laboratory Sciences,
National Center for Environmental Health, Centers for
Disease Control and Prevention (CDC), for analysis.
Whole blood Pb concentrations were determined at
the CDC using the PerkinElmer Inductively Coupled
plasma-dynamic reaction cell-Mass Spectrometer 6100
ELAN series DRC II, ELAN DRC II ICP-MS (PerkinEl-
mer SCIEX; Concord, ON, Canada) equipped with a
Meinhard nebulizer and cyclonic spray chamber
(PerkinElmer). In this multielement analytical technique,
blood samples are diluted with ≥18 MΩ/cm water and
with diluent containing 1% vol/vol tetramethylammo-
nium hydroxide, 0.5% disodium ethylenediamine tetraa-
cetate, 10% ethyl alcohol and 0.05% Triton X-100. Gold
is added to reduce intrinsic mercury memory effects.
Bismuth was added for the internal standardization of
Pb. The samples were prepared with the following ratio:
sample:water:diluent = 1:1:48. Pb was quantified on the
basis of the ratio of analyte signal to that of the internal
standard signal in peak hopping mode. The calibration
was external matrix-matched, control samples were
assessed along with participant samples and accuracy
was verified by the analysis of standard reference mate-
rial (SRM 955c) from the National Institute of Standards
and Technology. For Pb, the limit of detection in micro-
grams per deciliter was based upon the standardization
of base blood material and was 0.25 μg/dl (n = 284).
The interassay precision (relative standard deviations)
for lead was 3.2% at a level of 2.89 μg/dl.
Potential confounders
Covariates included age in years, sex, self-reported race
(African-American or Caucasian), body mass index
(BMI) and indicators of current smoking and alcohol
drinking. BMI was determined at a clinic evaluation by
measuring participants’ weight and height and calculat-
ing their BMI in kilograms per square meter. Current
smoking status was based on the answer to the question,
“Do you smoke cigarettes now?” and was dichotomized
to either current smoker or current nonsmoker. Current
alcohol drinking was based on the question, “Do you
currently drink alcoholic beverages?” and was dichoto-
mized to either current drinker or current nondrinker.
Because of demographic differences between the two
cohorts (the second follow-up sample, from 2006 to
2008, consists of older individuals, while the cohort
enrichment sample, from 2003 to 2004, was enriched
for younger individuals, men and African-Americans),
sequential modeling, including a cohort indicator, was
done to assess for any cohort effect on the models. First,
a test for interaction between a cohort indicator and
blood Pb level was found to be nonsignificant. Second,
inclusion of the cohort indicator as a confounder did
not alter effect estimates, and this term was therefore
dropped from the models.
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Statistical analysis
The natural log-transformed lead was used to assist in
the normalization of the distribution for blood Pb levels,
since the distribution of Pb levels on the original scale
was right-skewed. Truncation of ln Pb levels at the top
99.5th percentile was attempted because of a few high
values, but because this did not change the results, it
was not done in the final analyses. ln Pb variables were
used on the continuous scale and were also categorized
into quartiles. Descriptive statistics were calculated for
the whole sample and for those with complete data for
rOA and sxOA. One-way analysis of variance was per-
formed to test differences in the distributions of contin-
uous variables (for example, Pb levels) across subgroups
of interest.
The proportional odds assumption was tested for
three-level ordinal outcomes (laterality and severity). A
proportional odds model assumes that the relationship
between each independent variable of interest and the
ordinal outcome is similar across the incremental mea-
sures of outcome variables. This method generates a
single odds ratio to describe the comparison between
the highest category and the other combined categories
(for example, moderate or severe OA versus mild OA or
none) and between the highest categories and the lowest
category (for example, mild, moderate or severe OA ver-
sus none). If the proportional odds assumption was vio-
lated, a generalized logit model (which generates an
odds ratio for the comparison between each level and
the reference category) was used. The analysis was done
as person-based (for the laterality outcomes) and joint-
based (for the presence and severity outcomes). For
joint-based analyses, each participant was scored for two
observations, one for each knee, and generalized esti-
mating equations were used to account for intraperson
dependency of the data. All models were adjusted for
age, sex, race, BMI, current smoking and current alcohol
drinking.
Interactions between blood Pb levels and each of the
covariates were tested jointly in the models. Adjusted
P values of 0.1 or less were considered statistically sig-
nificant, and for those models with significant interac-
tions, two-way interaction terms were assessed. If these
individual P values were significant at the 0.1 level, then
appropriate subgroups were examined using stratifica-
tion and adjusted odds ratios (aORs) and 95% confi-
dence intervals (95% CIs) were calculated separately for
each subgroup. All analyses were performed using SAS
version 9.2 software (SAS, Inc., Cary, NC, USA).
Results
A total of 1,669 individuals with complete blood Pb
level data were available for the analysis, including 1,635
participants with complete data to define knee rOA
outcomes and 1,605 with complete data for the assess-
ment of knee sxOA outcomes. The average age of parti-
cipants was 65 years, and the participants’ mean BMI
was 31 kg/m2. About two-thirds of participants were
Caucasian women, of whom fewer than 25% reported
current smoking or drinking (Table 1). The median
blood Pb level in the sample was 1.8 μg/dl (range, 0.3 to
42.0 μg/dl). Knee rOA was present in 40% of the partici-
pants. Bilateral knee rOA was present in 23% of all par-
ticipants, and 26% had moderate to severe knee rOA.
Smaller numbers of participants had sxOA (present in
24%, bilateral in 11% and moderate or severe in 17%)
(Table 1). Higher ln Pb levels were seen in African-
Americans, men, those with lower BMI, current smokers
and current alcohol drinkers (Table 2). There were no
associations between ln Pb level and rOA or sxOA out-
comes in these unadjusted bivariate analyses. There
were no significant interactions between any of the cov-
ariates and ln Pb level for either rOA or sxOA
outcomes.
Knee rOA
Table 3 contains the aORs and 95% CIs for joint-based
associations between ln Pb level as a continuous variable
and the presence (versus absence) of the knee OA vari-
ables, as well as the covariates in the model. The odds
of having knee rOA were about 20% higher for every 1-
U increase in ln Pb level. In addition, the odds of having
more severe rOA were 26% higher for each 1-U increase
in ln Pb level (aOR, 1.26; 95% CI, 1.05 to 1.50). Using
person-based analyses, the odds of having bilateral rOA
compared with no rOA were 32% higher for each 1-U
increase in ln Pb level (aOR, 1.32; 95% CI, 1.03 to 1.70).
Table 1 Characteristics of the study populationa
Characteristic Knee rOA
(n = 1635)b
Knee sxOA
(n = 1605)b
Mean whole blood Pbc,
μg/dl (±SD)
2.4 (2.5) 2.4 (2.5)
Mean age, yr (±SD) 65.3 (11.0) 65.2 (11.0)
Mean BMI, kg/m2 (±SD) 31.2 (7.1) 31.2 (7.1)
African-Americans, n (%) 582 (35.6%) 573 (35.7%)
Women, n (%) 1085 (66.4%) 1069 (66.6%)
Current smoker, n (%) 259 (16.5%) 257 (16.6%)
Current drinker, n (%) 333 (21.2%) 329 (21.2%)
Knee outcomes rOA sxOA
Present, n (%) 659 (40.3%) 384 (23.9%)
Bilateral, n (%) 377 (23.1%) 170 (10.6%)
Moderate to severe,
n (%)
426 (26.1%) 271 (16.9%)
arOA, radiographic osteoarthritis; sxOA, symptomatic osteoarthritis; SD,
standard deviation; Pb, lead; BMI, body mass index; bsamples with complete
data for knee rOA and knee sxOA, respectively; cmedian, 1.8 μg/dl (range, 0.3
to 42.0 μg/dl).
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In joint-based analyses using ln Pb in quartiles (with
the lowest quartile, mean Pb 0.94 ± 0.20 μg/dl, as the
reference category), the highest quartile of ln Pb (mean
Pb, 4.92 ± 3.93 μg/dl) was associated with a 27%
increase in the odds of having knee rOA and 34% higher
odds of having more severe rOA (Table 4). There was a
linear trend for these associations (for presence, P for
trend = 0.113; for severity, P = 0.034), as increasing
quartiles of ln Pb were associated with consistently
higher odds of rOA outcomes. A similar trend was also
seen in person-based analyses for laterality, where the
odds of having bilateral rOA increased by 15%, 19% and
46%, respectively, for the following increasing quartiles
of ln Pb: Q2 aOR, 1.15; 95% CI, 0.78 to 1.70; Q3 aOR,
1.19; 95% CI, 0.80 to 1.76; and Q4 aOR, 1.46; 95% CI,
0.96 to 2.22.
Knee sxOA
In joint-based analyses of sxOA, the odds of having
sxOA were 16% higher for each 1-U increase in contin-
uous ln Pb (Table 3), while the odds of having more
severe sxOA were 17% higher (aOR, 1.17; 95% CI, 0.94
to 1.46). In person-based analyses, the odds of having
bilateral sxOA increased by 25% for each 1-U increase
in ln Pb (aOR, 1.25; 95% CI, 0.90 to 1.74).
For ln Pb in quartiles, the odds of having sxOA or
having more severe sxOA were 23% or 24% higher for
the highest ln Pb quartile compared to the lowest quar-
tile (Table 4). Unlike the results for rOA, the apparent
linear trend was not significant (for presence, P for
trend = 0.249; for severity, P for trend = 0.237). A simi-
lar pattern was seen for person-based analyses of lateral-
ity, where the odds of bilateral sxOA were 45% higher
in the highest quartile of ln Pb, although this was not
statistically significant (Q2 aOR, 1.16; 95% CI, 0.72 to
1.88; Q3 aOR, 1.01; 95% CI, 0.60 to 1.65; Q4 aOR, 1.45;
95% CI, 0.85 to 2.47).
Discussion
In this large community-based sample, we identified
small but significant increases in the presence, laterality
and severity of knee rOA with increasing levels of whole
blood Pb. A similar pattern of findings was seen for
sxOA, although it was not statistically significant, likely
because of smaller numbers of participants with sxOA
outcomes in the sample. The associations were strongest
for the most severe categories (moderate or severe, or
bilateral involvement). While blood Pb levels were
affected by demographic factors, being higher in
Table 2 Mean ln-transformed Pb levels by covariate
status (n = 1,669a)
Characteristics and strata Mean ln Pb (±SD) P valueb
Race <0.001
African-American 0.86 (0.70)
Caucasian 0.51 (0.54)
Sex <0.001
Women 0.52 (0.56)
Men 0.85 (0.68)
BMI <0.001
>30 0.58 (0.59)
≤30 0.68 (0.65)
Current smoking 0.006
No 0.57 (0.59)
Yes 0.97 (0.67)
Current drinking <0.001
No 0.56 (0.58)
Yes 0.91 (0.70)
Knee rOA 0.1
No 0.64 (0.64)
Yes 0.63 (0.60)
Knee sxOA 0.1
No 0.65 (0.64)
Yes 0.60 (0.60)
aFor rOA, n = 1,635; for sxOA, n = 1,605; for smoking, n = 1,605; for drinking,
n = 1,606; ln Pb, natural log-transformed lead; SD, standard deviation; rOA,
radiographic osteoarthritis; sxOA, symptomatic osteoarthritis; bP values
represent differences in mean ln Pb values between strata for each
characteristic.
Table 3 Adjusted odds ratios and 95% confidence intervals for associations between knee outcomes, continuous ln Pb
and covariates (joint-based analysis)a
Knee rOA Knee sxOA
Variable of interest (reference category) aORb 95% CI aORb 95% CI
ln Pb (per 1-U change) 1.20 1.01 to 1.44 1.16 0.93 to 1.45
Age (per year) 1.08 1.07 to 1.09 1.05 1.03 to 1.06
BMI (per kg/m2) 1.12 1.10 to 1.14 1.12 1.10 to 1.14
Sex (men) 0.96 0.77 to 1.21 1.24 0.94 to 1.63
Race (Caucasian) 1.08 0.85 to 1.36 0.84 0.64 to 1.11
Smoking (No) 0.60 0.43 to 0.85 0.59 0.38 to 0.91
Drinking (No) 0.75 0.57 to 1.00 0.72 0.50 to 1.03
aReference category is no rOA for rOA outcomes and rOA without symptoms for sxOA outcomes; aOR, adjusted odds ratio; CI, confidence interval; ln Pb, natural
log-transformed lead; rOA, radiographic osteoarthritis; sxOA, symptomatic osteoarthritis; BMI, body mass index; badjusted for age, sex, race and ethnicity, BMI,
current smoking and current drinking.
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African-Americans than in Caucasians, higher in men
than in women, higher in those with lower BMI and
higher in those who reported current smoking or cur-
rent alcohol drinking, the associations with knee rOA
remained statistically significant after adjustment for
these factors, and no significant interactions between
covariates were identified. Interestingly, while lower
BMI, smoking and alcohol drinking were all protective
factors in the prevalent rOA analysis, and all were asso-
ciated with higher Pb levels, even after adjustment for
these factors, we identified a significant effect of elevated
blood Pb level on the presence of rOA. This suggests to
us that this ubiquitous environmental toxicant may have
a role in knee OA.
The blood Pb levels seen in our study were compar-
able to those reported in other studies of the health
effects of blood Pb levels in nonoccupationally exposed
individuals [10,19,20,24,26,38-40]. These levels are far
below the threshold for chelation therapy (50 μg/dl or
higher with severe symptoms, or greater than 100 μg/dl
with or without symptoms [41]).
The associations between rOA and whole blood Pb
levels could be due to a detrimental effect of Pb on the
joints leading to structural damage, or the increased Pb
levels could reflect an increased rate of bone turnover in
OA leading to increased release of Pb from bone. The
associations between blood Pb level and sxOA could be
related to modulation of pain perception by Pb itself,
given its known neurotoxic effects [42]. Although we
are unable to draw any causal conclusions on the basis
of this cross-sectional data analysis, there is support for
a potential causative effect of Pb in OA. Pb is locally
toxic to bone, and intraarticular Pb, as demonstrated
with retained Pb bullets, can lead to arthritis, synovitis
and even systemic toxicity [43,44]. Mice exposed to Pb
have delayed fracture healing and reduced endochondral
maturation [31], suggesting a potential impact of Pb on
bone remodeling, a process seen in OA. A study of
trace elements in bone found significantly lower Pb con-
centrations in femoral heads of patients undergoing total
hip replacement for OA than in those with hip fracture
or in necropsy controls, suggesting release of Pb into
the circulation from the remodeling OA bone [45]. In
contrast, a study of articular cartilage and subchondral
bone from individuals without bone disease or known
Pb exposure showed differential specific accumulation of
Pb in the tidemark region [29]. The tidemark represents
the transition between calcified and uncalcified cartilage,
an area known to advance, duplicate and develop clefts
during the development of OA. These findings suggest
that Pb may have a direct effect on the joints in OA
beyond the release of Pb into the circulation as a conse-
quence of bone remodeling. It is also possible that early
changes in OA lead to the release of Pb from bone, thus
aggravating joint damage. A mechanism by which Pb
exposure may increase the susceptibility of osteoblasts
to environmental toxins has recently been proposed
[46], and it may be that regardless of causality, once the
Pb levels are increased, a cycle of increased susceptibility
to toxic damage may begin.
Another mechanism by which Pb may contribute to
pathology in OA is through nitric oxide (NO), an
important mediator of oxidative stress. Chondrocytes
have long been known to express inducible nitric oxide
synthase (NOS) [47], and recently a greater role for NO
in the pathogenesis of OA has been recognized [48,49].
Increased production of NO and associated molecules
has been noted in OA joints and specifically in chondro-
cytes [48]. Beneficial effects of NO on chondrocytes and
the cartilage matrix, mediated through constitutive
NOS, as well as negative effects mediated by inducible
NOS, have been identified [48,50]. Differential effects on
pain based on the pathway and local environment where
NO is produced have also been found [48,51]. Interest-
ingly, and pertinent to the current study, Pb can both
increase reactive oxygen species and reduce the
Table 4 Adjusted odds ratios and 95% confidence intervals for associations between ln Pb in quartiles and knee
outcomes (joint-based analysis)a
Knee rOA Knee sxOA
Knee outcomesb ln Pb quartilesc aORd 95% CI ln Pb quartilesc aORd 95% CI
Q2 1.09 0.81 to 1.48 Q2 1.10 0.77 to 1.56
Presence Q3 1.18 0.89 to 1.58 Q3 1.16 0.83 to 1.62
Q4 1.27 0.93 to 1.74 Q4 1.24 0.86 to 1.79
Q2 1.07 0.80 to 1.43 Q2 1.06 0.75 to 1.51
Severitye Q3 1.25 0.95 to 1.65 Q3 1.16 0.83 to 1.62
Q4 1.34 0.99 to 1.81 Q4 1.23 0.85 to 1.77
aaOR, adjusted odds ratio; CI, confidence interval; ln Pb, natural log-transformed lead; rOA, radiographic osteoarthritis; sxOA, symptomatic osteoarthritis; Q,
quartile; breference category is no rOA for rOA outcomes, no sxOA for sxOA presence and rOA with no symptoms for sxOA severity outcomes; cmean Pb (±SD) in
micrograms per deciliter level by quartile: Q1 (reference), 0.94 (±0.20); Q2, 1.5 (±0.15); Q3, 2.13 (±0.24); Q4, 4.92 (±3.93); dadjusted for age, sex, race and ethnicity,
BMI, current smoking and current drinking; eproportional odds assumption met; a common OR describes the relationship between mild, moderate or severe
compared to none, or between moderate or severe compared to mild or none.
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availability of NO, thereby increasing potential oxidative
stress [52]. In studies of Pb-induced hypertension, a
cycle of increased oxidative stress leading to nuclear fac-
tor-B-mediated inflammation and apoptosis, followed
by additional oxidative stress from the released inflam-
matory mediators and subsequent increased inflamma-
tion, has been hypothesized [52] and is thought to be
aggravated by Pb exposure, which contributes to inflam-
mation, apoptosis and reduced NO production [53].
Increased Pb levels may therefore lead to more severe
rOA and more severe symptoms, as seen in the current
analysis, by contributing to increased inflammation and
oxidative stress mediated through a reduction in NO.
There are some limitations to the current study. Whole
blood Pb measurements were used as an economical and
readily available biomarker for Pb exposure [54,55].
Although specialized X-ray fluorescence techniques to
assess bone Pb are considered the “gold standard” for
measurement of Pb storage, this procedure is expensive
and not widely available [54,55]. Since blood Pb levels
reflect recent exposure as well as the mobilization of Pb
from bone [19,54], and since blood Pb level has been
associated with all-cause mortality, cardiovascular disease
and renal disease [25,26,38-40,56], this measure of Pb
was used instead. The current study is also limited
because of its cross-sectional design, although the poten-
tial for future longitudinal studies of Pb in this popula-
tion exist. The strengths of this study include its
community-based biracial sample, large sample size and
the availability of high-quality radiographic and sympto-
matic outcome data gathered in a standard manner.
Conclusions
We have identified a novel association between whole
blood Pb levels and the presence and severity of rOA
and sxOA of the knee. These observations were seen in
both men and women and in both African-Americans
and Caucasians. This could represent a direct toxic
effect of Pb on joint tissues, or it may represent an
indirect effect of increased Pb release from bone second-
ary to bone remodeling. Pb may represent a novel, mod-
ifiable risk factor in patients with OA. Longitudinal
studies in this and other populations will help to clarify
and validate these findings.
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